Glenmark Pharmaceuticals Specialty SA has achieved a significant regulatory milestone with the U.S. FDA's final approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. The approval comes with a valuable 180-day competitive generic therapy exclusivity period, positioning the company as the first approved applicant for this respiratory medication.

Product Specifications and Market Positioning

The FDA has determined that Glenmark's Fluticasone Propionate Inhalation Aerosol is bioequivalent and therapeutically equivalent to the reference listed drug FloVent HFA Inhalation Aerosol, 44 mcg, manufactured by GlaxoSmithKline Intellectual Property Ltd. England. This bioequivalence determination validates the product's therapeutic effectiveness and safety profile.

Competitive Generic Therapy Designation

Glenmark has been granted Competitive Generic Therapy designation for this product and qualifies as the "first approved applicant" under section 505(j)(5)(B)(v)(III) of the FD&C Act. This status entitles the company to 180 days of CGT exclusivity upon commercialization, providing a significant competitive advantage in the market entry phase.

Market Opportunity and Commercial Launch

According to IQVIA sales data for the 12-month period ending January 2026, the FloVent HFA Inhalation Aerosol, 44 mcg market achieved annual sales of approximately USD 520.00 million. The product will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA starting in March 2026.

Marc Kikuchi, President & Business Head, North America, commented on the approval: "Receiving approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation marks an important milestone in strengthening our respiratory portfolio in the U.S. The CGT designation and first approved applicant status reflect the technical expertise and dedication of our teams in bringing complex inhalation therapies to market."

Strategic Impact on Respiratory Portfolio

This approval further strengthens Glenmark's respiratory portfolio in the U.S. market and demonstrates the company's commitment to expanding access to quality inhalation therapies. The launch represents Glenmark's continued focus on developing complex generic formulations in the respiratory segment, particularly inhalation products that require specialized manufacturing capabilities and regulatory expertise.

Source:

Glenmark Pharmaceuticals Inc., USA has announced the upcoming launch of Sodium Phosphates Injection USP in three distinct vial presentations, marking a significant expansion in the company's injectable pharmaceutical portfolio. The launch is scheduled to commence in April 2026, with the product being bioequivalent and therapeutically equivalent to the reference listed drug.

Product Specifications and Regulatory Approval

The pharmaceutical company will introduce Sodium Phosphates Injection USP in three specific formulations: 15 mM P/5 mL, 45 mM P/15 mL, and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials. The product has received regulatory approval as bioequivalent and therapeutically equivalent to the reference listed drug, Sodium Phosphates Injection USP, 45 mM P/15 mL (3 mM P/mL), of Hospira, Inc. [NDA 018892].

Market Opportunity and Sales Data

According to IQVIA sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP market achieved annual sales of approximately $66.8 million. This market valuation represents a substantial commercial opportunity for Glenmark's entry into this therapeutic segment, with the company positioned to capture market share through its bioequivalent formulation.

Strategic Leadership Commentary

Marc Kikuchi, President & Business Head, North America, commented on the launch, stating the company looks forward to strengthening its commitment to bring quality and affordable alternatives for patients while further expanding the portfolio of products within the institutional channel. The launch aligns with Glenmark's broader strategy to enhance its presence in the injectable pharmaceuticals segment.

Regulatory and Therapeutic Equivalence

The 15 mM P/5 mL and 150 mM P/50 mL presentations are expected to have the same therapeutic effect as the listed drug product upon which the FDA relied as the basis of safety and effectiveness. Glenmark's product is approved specifically for the indications listed in the company's approved label and maintains compliance with regulatory standards for bioequivalence and therapeutic equivalence.